The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... to have two Phase 2 product candidates in our portfolio, each with a distinct mechanism of action, that can potentiate ...

Dr. Zocca continued, “Our T-win platform generates off-the-shelf therapeutic cancer vaccine candidates with a unique mechanism of action, capable of both ... IO102-IO103 in combination with KEYTRUDA ® ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Abstract title: “ICT01 and pembrolizumab in combination elicit deep and durable ... As demonstrated by its lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full ...

Keytruda (pembrolizumab) is a prescription drug ... What’s Keytruda’s mechanism of action? And what are signs that it’s working? Keytruda’s mechanism of action (how it works) is to promote ...

KVA12123 provides a novel approach to address immune suppression in the tumor microenvironment with a mechanism of action that is differentiated and complementary with T cell focused therapies.

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...